The recently concluded 2024 ASCO Annual Meeting in Chicago, Illinois, showcased groundbreaking advancements in the field of oncology pharmacy practice. Here are some of the key findings from the sessions that are revolutionizing cancer treatment
Lung Cancer
-
CROWN Trial
The phase 3 CROWN trial highlighted the significant progression-free survival advantage of lorlatinib over crizotinib in patients with ALK-positive non–small cell lung cancer.
-
LAURA Trial
Osimertinib was shown to improve PFS in patients with EGFR-mutated NSCLC, paving the way for enhanced treatment options.
Lymphomas
-
UPCC15420 Trial
Researchers are testing a fourth-generation anti-CD19 CAR T-cell therapy modified to secrete IL-18, showing promise in boosting longer-term remission in non-Hodgkin lymphoma.
Chronic Myelogenous Leukemia
-
ASC4FIRST Trial
Asciminib demonstrated superior major molecular response rates and better tolerability profiles than other TKIs in patients with newly diagnosed CML.
Colorectal Cancer
-
PROCEADE-CRC-01 Trial
The anti-CEACAM5 antibody-drug conjugate M9140 showed early potential in patients with metastatic colorectal cancer, offering a ray of hope in advanced disease.
Breast Cancer
-
DESTINY-Breast06 Trial
Fam-trastuzumab deruxtecannxki showed significant improvement in PFS compared with standard chemotherapy in patients with metastatic breast cancer, presenting a paradigm shift in treatment.
Acute Myeloid Leukemia
-
Abstract 6507
Reducing the duration of venetoclax in combination therapy resulted in similar remission rates with lower toxicities, providing a more patient-friendly treatment option.
Melanoma
-
IMC-F106C Trial
IMC-F106C showed promise in the treatment of cutaneous melanoma, offering a potential new therapy for this aggressive disease.
General ASCO News
-
Partnership with American Cancer Society
ASCO's collaboration with the American Cancer Society aims to provide patients with a credible database of resources for cancer education and support.
-
GLP-1 Receptor Agonists Study
Glucagon-like peptide-1 receptor agonists were found to reduce the risk of obesity-related cancers, presenting a promising alternative to bariatric surgery.
These findings from the 2024 ASCO Annual Meeting underscore the continuous strides being made in the field of oncology, offering hope and improved outcomes for patients battling various types of cancer.